5-Amino-1MQ (also known as 5-amino-1-methylquinolinium) is a performance-enhancing peptide studied for its effects on fat loss, weight loss, metabolic health. 5-Amino-1MQ is an oral NNMT inhibitor studied in rodents for fat loss and raising NAD+. No human trials; prohibited by WADA under class S0.
5-Amino-1MQ is an orally bioavailable small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), the enzyme that consumes nicotinamide and S-adenosyl methionine to produce 1-methylnicotinamide. Blocking NNMT is intended to raise intracellular NAD+ and S-adenosyl methionine, especially in adipose tissue, where rodent work has reported increased fat-cell energy expenditure and reduced diet-induced obesity. Despite being sold and discussed alongside peptides, it is not a peptide but a methylquinolinium small molecule.
Overview
Human evidence is absent: there are no completed or active clinical trials, no regulatory approval in any jurisdiction, and every efficacy result to date comes from cell-culture or rodent models.
Because no governmental regulatory health authority has approved it for human therapeutic use, it falls under class S0 (non-approved substances) of the WADA Prohibited List, meaning 5-Amino-1MQ is prohibited by WADA at all times, both in and out of competition.
Mechanism of action
Oral small-molecule NNMT inhibitor that raises NAD+ and S-adenosyl methionine to boost fat-cell energy expenditure. Studied only in rodents for fat loss; no human trials exist.
Reported effects
Effects reported in the literature and from preclinical models include:
- Combined with a low-fat diet, NNMT inhibition produces dramatic reductions in whole-body adiposity and weight in diet-induced obese mice, rapidly normalizing them toward age-matched lean controls. [2] Preclinical
- NNMT inhibition alongside a reduced-calorie diet shifts the gut microbiome toward a leaner-associated profile in obese mice, decreasing Erysipelatoclostridium and increasing Lactobacillus. [2] Preclinical
- Pharmacologic NNMT inhibition reduces tumor growth and enhances the apoptotic effect of anti-PD-L1 immunotherapy in bladder cancer mouse models. [1] Preclinical
Evidence grades: FDA approved Phase III Phase II Phase I Preclinical Anecdotal
Natty status
5-Amino-1MQ is classified as not natty. It appears on the WADA prohibited list and is banned by major natural bodybuilding federations.[3] Use of this compound places the athlete in the enhanced category rather than the natural category in competitive contexts.
Research
The peptide has been the subject of 2 studies and reference works collected on this site. The full bibliography is in § External links below.
Related compounds
Other peptides in this catalogue with overlapping mechanisms or status:
References
- ^ NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. Recent
- a b Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Recent
- a b World Anti-Doping Agency. (2026). Prohibited List 2026.
This page was last updated on July 17, 2026, at 16:18 (UTC).
Research last reviewed on July 17, 2026.
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply.